Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
The cost to treat cancer in the United States could reach $156 billion in 2020, according to the National Cancer Institute. And innovative medications have a significant impact on the cost of care.
Gene therapy, which got its start in the 1960s, is finally starting to take hold.
High-cost treatments for rheumatoid arthritis has fueled the need to better understand their value to healthcare systems and patients.
Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.